ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Omeros Corporation (OMER) Report Updated: Jun 27, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Omeros Corporation (OMER)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Pharmaceuticals
Competitors: JNJ,HSKA,AMPE,TBPH

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

Omeros Corporation© quotemedia

Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery. The company’s clinical products include OMS721 that is in Phase II clinical trials for the treatment of various complement-mediated disorders, including complement-mediated thrombotic microangiopathies; OMS824, which is in Phase II clinical trials for the treatment of CNS disorders comprising schizophrenia and Huntington's disease; and OMS103 that has completed Phase III clinical trials for use during arthroscopic procedures, such as partial meniscectomy surgery. Its clinical programs also comprise OMS405, which is in Phase II clinical trials for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase I/II clinical trials for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical programs also comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. In addition, its preclinical products consist of GPR17 for the treatment of demyelinating disorders; G protein-coupled receptor platform for multiple disorders across therapeutic area; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.